Patient selection for whole brain radiotherapy (WBRT) in a large lung cancer cohort: Impact of a new Dutch guideline on brain metastases
Authors:
- Lizza E. L. HendriksLHLizza E. L. Hendriks
- Esther G. C. TroostETEsther G. C. Troost
- Allan StewardASAllan Steward
- Gerben P. BootsmaGBGerben P. Bootsma
- Katrien De JaegerKJKatrien De Jaeger
- Ben E. E. M. van Den BorneBBBen E. E. M. van Den Borne
- Anne-Marie C. DingemansADAnne-Marie C. Dingemans
- 23 April 2014
- journal article
- research article
- Published by Medical Journals Sweden AB in Acta Oncologica
- Vol. 53 (7) , 945-951
Abstract
Median survival after diagnosis of brain metastases is, depending on the Recursive Partitioning Analysis (RPA) classes, 7.1 (class I) to 2.3 months (class III). In 2011 the Dutch guideline on brain metastases was revised, advising to withhold whole brain radiotherapy (WBRT) in RPA class III. In this large retrospective study, we evaluated the guideline's use in daily practice. Data of 428 lung cancer patients undergoing WBRT for brain metastases (2004-2012) referred from three Dutch hospitals were retrospectively analyzed. Details on Karnofsky performance score (KPS), age, control of primary tumor, extracranial metastases, histology, and survival after diagnosis of brain metastases were collected. RPA class was determined using the first four items. In total 327 patients had non-small cell lung cancer (NSCLC) and 101 small cell lung cancer (SCLC). For NSCLC, 6.1%, 71.9%, and 16.2% were classified as RPA I, II, and III, respectively, and 5.8% could not be classified. For SCLC this was 8.9%, 66.3%, 14.9%, and 9.9%, respectively. Before the revised guideline was implemented, 11.3-21.3% of WBRT patients were annually classified as RPA III. In the year thereafter, this was 13.0% (p = 0.646). Median survival (95% CI) for NSCLC RPA class I, II, and III was 11.4 (9.9-12.9), 4.0 (3.4-4.7), and 1.7 (1.3-2.0) months, respectively. For SCLC this was 7.9 (4.1-11.7), 4.7 (3.3-6.1), and 1.7 (1.5-1.8) months. Although it is advised to withhold WBRT in RPA class III patients, in daily practice 11.3-21.3% of WBRT-treated patients were classified as RPA III. The new guideline did not result in a decrease. Reasons for referral of RPA III patients despite a low KPS were not found. Despite WBRT, survival of RPA III patients remains poor and this poor outcome should be stressed in practice guidelines. Therefore, better awareness amongst physicians would prevent some patients from being treated unnecessarily.Keywords
This publication has 18 references indexed in Scilit:
- Interim Data from the Medical Research Council QUARTZ Trial: Does Whole Brain Radiotherapy Affect the Survival and Quality of Life of Patients with Brain Metastases from Non-small Cell Lung Cancer?Clinical Oncology, 2013
- The clinical utility of prognostic scoring systems in patients with brain metastases treated with radiosurgeryRadiotherapy and Oncology, 2013
- Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of Oncology, 2012
- Validation of the RTOG recursive partitioning analysis (RPA) classification for small-cell lung cancer–only brain metastasesInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2007
- Brain metastases: epidemiology and pathophysiologyJournal of Neuro-Oncology, 2005
- Results of the whole-brain radiotherapy for patients with brain metastases from lung cancer: The RTOG RPA intra-classes analysis.Acta Oncologica, 2005
- Brain metastases in locally advanced nonsmall cell lung carcinoma after multimodality treatmentCancer, 2002
- Identification of prognostic factors in patients with brain metastases: a review of 1292 patientsInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 1999
- Recursive partitioning analysis (RPA) of prognostic factors in three radiation therapy oncology group (RTOG) brain metastases trialsInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 1997
- Value of radiation therapy in the management of intracranial metastasesCancer, 1961